Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated. Although neoadjuvant-targeted therapy with EGFR-TKI and ALK-TKI showed good efficacy, there is no report of neoadjuvant-target...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2022-08-01
|
| Серія: | Frontiers in Oncology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fonc.2022.961539/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|